Marie Carlo, MD | Authors

May 02, 2022

Brian Rini, MD, summarizes the thoughts of his colleagues on the use of lenvatinib plus pembrolizumab to treat advanced renal cell carcinoma.

May 02, 2022

A panel of oncologists look at what’s in the pipeline for advanced renal cell carcinoma, including trials and treatment options.

May 02, 2022

Two kidney cancer experts explore the current unmet needs for patients with advanced renal cell carcinoma.

April 21, 2022

A look at the current unmet needs in front-line renal cell carcinoma treatment.

April 21, 2022

Oncologists review quality of life data for patients with renal cell carcinoma receiving lenvatinib plus pembrolizumab combination treatments.

April 19, 2022

Kidney cancer experts explain how they dose lenvatinib in advanced renal cell carcinoma treatment to mitigate toxicities.

April 19, 2022

An explanation of dosing strategies when treating patients with renal cell carcinoma in the first-line with lenvatinib.

April 19, 2022

Experts discuss the safety of treating renal cell carcinoma with lenvatinib within different patient risk populations.

April 19, 2022

Possible comorbidities and other risk factors in advanced renal cell carcinoma that would affect potential treatment regimens.

April 04, 2022

A look at the factors considered in choosing an appropriate combination treatment for advanced renal cell carcinoma.